HMPA-catalyzed transfer hydrogenation of 3-carbonyl pyridines and other N-heteroarenes with trichlorosilane

Article abstract of DOI:10.3390/molecules24030401

A method for the HMPA (hexamethylphosphoric triamide)-catalyzed metal-freetransfer hydrogenation of pyridines has been developed. The functional group tolerance of the existing reaction conditions provides easy access to various piperidines with ester or ketone groups at the C-3 site. The suitability of this method for the reduction of other N-heteroarenes has also been demonstrated. Thirty-three examples of different substrates have been reduced to designed products with 45–96% yields.

Full text of DOI:10.3390/molecules24030401

molecules
Article
HMPA-Catalyzed Transfer Hydrogenation of
3-Carbonyl Pyridines and Other N-Heteroarenes
with Trichlorosilane
Yun Fu 1,2 and Jian Sun 1,
*
1
Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China; fy860401@163.com
University of Chinese Academy of Sciences, Beijing 100049, China
2
*
Correspondence: sunjian@cib.ac.cn; Tel.: +86-28-8522-2753
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Received: 22 December 2018; Accepted: 19 January 2019; Published: 22 January 2019
Abstract: A method for the HMPA (hexamethylphosphoric triamide)-catalyzed metal-free transfer
hydrogenation of pyridines has been developed. The functional group tolerance of the existing
reaction conditions provides easy access to various piperidines with ester or ketone groups at the
C-3 site. The suitability of this method for the reduction of other N-heteroarenes has also been
demonstrated. Thirty-three examples of different substrates have been reduced to designed products
with 45–96% yields.
Keywords: HMPA; transfer hydrogenation; trichlorosilane; pyridines
1. Introduction
Piperidines are very important structural building blocks of numerous biologically active
compounds, such as the Topo inhibitor, the Chk1 inhibitor, Tiagabine and Focalin XR [1].
The catalytic hydrogenation of pyridines provides one of the most straightforward methods to access
piperidines [2–18], although it is essential to overcome some inherent challenges presented by catalyst
deactivation and pyridine dearomatization. In the last decade, various transition-metal catalyst systems
have been studied for the direct hydrogenation of pyridines, but the metal-free catalytic reduction of
pyridines is a great challenge [19–24].
In recent years, frustrated Lewis base pairs have been proven as efficient catalyst systems for
the regio- and chemoselective reduction of pyridines with various reducing agents. In particular,
Stephan [25] and Du [26], respectively, reported the metal-free organoborane-catalyzed hydrogenation
of pyridines with H2. Later on, Du [27] developed a method for the metal-free organoborane catalyzed
transfer hydrogenation of pyridines with ammonia boranes. Chang [28] and Wang [29] reported
the B(C6F5)3 catalyzed reduction of pyridines with Et2SiH2 and PhMe2SiH, respectively (Figure 1).
For the reduction of the 3-carbonyl pyridines, Rueping reported the first example of organocatalytic
transfer hydrogenation of 3-carbonyl pyridines with Hantzsch ester for the preparation of chiral
1,4-dihydropyridine (DHP) derivatives [30]. Although a variety of 3-carbonyl piperidines derivatives
could be prepared with these methods, there are still some drawbacks: (1) For most of these reactions,
a high temperature and (2) high pressure of H2 was required. Therefore, the search for new methods
for the reduction of 3-carbonyl pyridines still remains a challenging task.
Molecules 2019, 24, 401; doi:10.3390/molecules24030401
www.mdpi.com/journal/molecules

Molecules 2019, 24, 401
2 of 15
Figure 1. Selected examples for the synthesis of piperidines through the catalytic reduction of pyridines.
Trichlorosilane with a Lewis base as an activator is a well-known unsaturated double bond
reduction method. Its strength has been well demonstrated by others and ourselves in terms of
asymmetric reduction of double bonds [31–38]. However, to the best of our knowledge, the reduction
of pyridines by use of this system still presents a great challenge, and no successful protocol has been
reported. In our previous study, we found trichlorosilane could activate the imine substrate through
coordination of the nitrogen atom. A similar coordination was also found when trichlorosilane and
pyridines were added together. Thus, we envisioned that pyridines would be reduced by trichlorosilane
with a proper Lewis base activator. Here in, we wish to communicate the results of our study and
present a highly effective new method to reduce 3-carbonyl pyridines under an organic Lewis base
activated trichlorosilane system.
2. Results and Discussion
To implement our design, phenyl(pyridin-3-yl)methanone 1a was used as a model substrate
to test the catalytic activity of various commercially available Lewis bases. We found that the
reduced product could be obtained with 49% and 37%, respectively, when 0.2 equivalent of
HMPA (hexamethylphosphoric triamide) or POPh3 were used. However, only a trace amount of
reduced product could be detected when DMF (N,N-dimethylformamide) was used, which has
been proven as an efficient catalyst for the reduction of C=O and C=N bonds with trichlorosilane.
Dichloromethane was the most suitable solvent for this reaction. An 86% yield could be obtained
when six equivalents of trichlorosilane were added as a reducing agent. The yield could be increased
further to 96% when the reaction was stirred at 25 ◦C for 24 h. Decreasing the amount of HMPA to
10 mol% and 5 mol%, respectively, both caused a clear drop in the yield. After a careful investigation,
we identified the best reaction conditions in which the substrate 1a was reduced with trichlorosilane
(6.0 equivalent) under the catalysis of HMPA (20 mol%) in DCM (dichloromethane) at 25 ◦C for 24 h
(Table 1).

Molecules 2019, 24, 401
3 of 15
Table 1. Optimization of reaction conditions a.
O
O
Ph
Ph
LB, HSiCl3
N
Cl
N
1a
H2
2a
◦
Yield (%) b
Entry
Solvent
LB (Equiv.)
Temp ( C)
1
2
3
4
5
6
7
8
9
10
11
12 c
13 d
14 e
15 f
16 f
17 f
DCM
DCM
DCM
DCM
DCM
THF
CHCl3
CCl4
DCE
toluene
MeCN
DCM
DCM
DCM
DCM
DCM
DCM
HMPA (0.2)
DMF (0.2)
0
0
0
49.0
trace
37.0
38.0
82.0
64.0
76.0
trace
77.0
trace
trace
60.0
81.0
86.0
96.0
82.0
54.0
POPh3 (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.2)
HMPA (0.1)
HMPA (0.05)
−10
25
25
25
25
25
25
25
25
25
25
25
25
25
a
Unless otherwise specified, all reactions were performed with pyridines (0.1 mmol), HMPA and HSiCl3 (0.6 mmol)
in solvent (1 mL) for 12 h. b Isolated yield. c HSiCl3 (0.4 mmol). d HSiCl3 (0.5 mmol). e HSiCl3 (0.8 mmol). f Reaction
time is 24 h. hexamethylphosphoramide (HMPA).
With the optimized reaction conditions in hand, the scope and limitations for the substrates
were investigated. We found a series of phenyl(pyridin-3-yl)methanone derivatives could be
reduced under the existing reaction conditions to get the desired product with good yields
(Figure 2). The desired products 2b–2h were obtained with 62–91% yields when the phenyl
group of phenyl(pyridin-3-yl)methanone was replaced with other aryl and alkyl substituents.
The 3,5-disubstituted pyridines could also be reduced under the existing reaction conditions.
The substituents of the 5-position of the pyridine ring could be aryl and alkyl groups. The 5-phenethyl
and 5-methyl substituted substrates could be reduced to the desired products 2i and 2j with 61%
and 77% yields, respectively. When the 5-position substituent groups of pyridines were Ph, 4-MePh,
4-FPh and 1-napthyl, these pyridines could be reduced to 3,5-disubsitituted piperidines with 82–88%
yields. The substrates with a hetero aromatic group at the 5-position of the pyridines are also
tolerated. The desired products 2o and 2p were obtained with 73% and 82% yields, respectively, when
the thiopen-2-yl and thiopen-3-yl substituted substrates were reduced under the existing reaction
conditions. Next, we found that the 3,6-disubstituted substrates could be reduced with moderate
yields. The desired reducing products 2q–2s could be obtained with 40–53% yields.
Ethyl nicotinate and its 5-position substituted derivatives are tolerated under the existing
reaction conditions. Ethyl nicotinate was reduced to the corresponding product 2t with a 75% yield.
The 5-methly substituted ethyl nicotinate was reduced with a 41% yield, and the 5-Ph, 4-MeOPh and
4-FPh substituted ethyl nicotinate were reduced to their corresponding products 2v
yields. The 5-BnO substituted ethyl nicotinate could also be reduced to the corresponding product 2y
with a 45% yield. In order to confirm the relative configuration of the main product, compounds
and were synthesized according the literature, and the trans product was confirmed to be the main
product [39].
–2x with 75–76%
5
6

Molecules 2019, 24, 401
4 of 15
Figure 2. Substrate scope of the HMPA-catalyzed reduction of pyridines.
Pyridine derivatives such as 3-Br, 3-CF3, 3-NO2, and 3-CN substituted pyridines could not be reduced
under the existing reaction conditions. However, other N-heteroarenes such as quinoxaline (3a) and
2-phenylquinoxaline (3b) could be reduced to their tetrahydroquinoxaline derivatives 4a [29] and 4b [40]
with high yields. The substrates 3c and 3d were partially reduced to the products 4c and 4d. Quinolone
(
3e) and isoquinoline (3f) were reduced to products 4e
1,5-Naphthyridine (3g) and 1,10-phenanthroline (3h) could only be partially reduced to the products 4g
and 4h [43] (Figure 3). All attempts to achieve the fully reduced products of 3c, 3d, 3g and 3h have failed.
[
41] and 4f
[
41], respectively, with moderate yields.
[
42
]

Molecules 2019, 24, 401
5 of 15
Prodcut 4
Substrate 3
N
H
N
N
R1
N
H
R1
3a
4a
, R = H
, R = H, 92%
3b
4b
, R = Ph, 91%
, R = Ph
Cl
Cl
N
N
N
NH
3c
4c
, 91%
Cl
Cl
N N
HN N
3d
4d
, 86%
N
N
N
H
3e
3f
4e
, 72%
N
NH
4f
, 61%
H
N
N
3g
N
4g
, 75%
N
N
N
4h
HN
, 61%
3h
Figure 3. Substrate scope of the HMPA-catalyzed reduction of N-heteroarenes.
In order to shed light on the mechanistic pathway, in situ NMR analysis was performed. We first
found that ethyl nicotinate could form a complex with HSiCl3 when the reaction was set in CDCl3
under the otherwise identical reaction conditions. An obvious chemical shift in the aromatic region
could be detected when HSiCl3 was added to the solution of 1t. Besides the signals of the designed
products, a group of peaks that matched the intermediate
C were also detected at the beginning.
The intensity of these peaks would decrease with the addition of water. At the end of the reaction, only
the peaks of designed product and HMPA could be detected (Figure 4).

Molecules 2019, 24, 401
6 of 15
1
Figure 4. H-NMR spectra for mechanism studies.
Based on the above observations and precedents indicating a stepwise process in the reduction
of unsaturated pyridines [27], we proposed a possible mechanistic pathway for the present
HMPA-catalyzed reduction of pyridines (Figure 5). The first step was assumed to be the formation of
a HSiCl3 and substrate complex, followed by the hydride attack at the C-4 position to produce the
1,4-dihydropyidine intermediate,
reduced to with HSiCl3 under the catalysis of HMPA. The
since only the intermediate could be detected and isolated from the reaction. The proton which
A
, which will transfer to
B
in the presence of a proton, and then be
D
D
to step is the rate-determining step,
E
D
is coming from the hydrochloride that is formed by the hydrolysis of HSiCl3 is important for the
existing reaction.

Molecules 2019, 24, 401
7 of 15
Figure 5. Proposed mechanism of HMPA-catalyzed reduction of ethyl nicotinate with HSiCl3.
In order to illustrate the synthetic potential of these methodologies, a gram-scale reaction was
carried out using 1t as the substrate. Fortunately, the desired product, 2t, was obtained in a yield of
69% (Figure 6).
Figure 6. The gram-scale reaction of 1t.
3. Materials and Methods
All solvents used in the reactions were distilled from the appropriate drying agents prior to
use. All substrates were analogously prepared and characterized as reported in the Supplementary
Materials. Reactions were monitored by thin layer chromatography, using silica gel HSGF254 plates.
Flash chromatography was performed using silica gel HG/T2354-92. 1H- and 13C-NMR (400 and
100 MHz, respectively) spectra were recorded in CDCl3. The 1H-NMR chemical shifts are reported
in ppm (
δ) relative to tetramethylsilane (TMS), with the solvent resonance employed as the internal
standard (CDCl3,
δ
7.26 ppm). Data are reported as follows: Chemical shift, multiplicity (s = singlet,
d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, dd = double doublet), coupling constants
(Hz) and integration. 13C-NMR chemical shifts are reported in ppm from tetramethylsilane (TMS) with
the solvent resonance as the internal standard (CDCl3,
δ 77.0 ppm). ESIMS (Electron Spray Ionization
Mass Spectrometry) spectra were recorded on BioTOF Q (Bruker, Billerica, MA, USA).

Molecules 2019, 24, 401
8 of 15
3.1. Reduction of Pyridines and N-Heteroaromatics
Under an argon atmosphere, pyridine
1
or N-heteroaromatic
3
(0.10 mmol) and HMPA (3.5 mg,
0.02 mmol) were added in anhydrous DCM (0.7 mL) and stirred at room temperature for 10 min,
and then trichlorosilane (2.0 M, 0.3 mL) was added. The reaction was stirred at room temperature for
24 h, quenched with H2O, and then the pH was adjusted to ~7–8 with saturated NaHCO3. The mixture
was extracted with EtOAc (3
anhydrous Na2SO4, concentrated under reduced pressure and purified with column chromatography
(silica gel, DCM/MeOH/TEA = 10/1/0.1) to afford a pure product.
×
5 mL). The combined organic layers were washed with brine, dried over
1
3-Benzoylpiperidin-1-ium Chloride (2a). Colorless oil. H-NMR (400 MHz, CDCl3):
δ 7.97–7.95 (m, 2H),
7.58–7.55 (m, 1H), 7.49–7.45 (m, 2H), 3.64–3.46 (m, 1H), 3.27–3.24 (m, 3H), 3.10 (d, J = 12.3 Hz, 1H), 2.90
(dd, J = 12.4, 9.9 Hz, 1H), 2.71–2.69 (m, 1H), 2.04–2.02 (m, 1H), 1.84–1.56 (m, 3H). 13C-NMR (101 MHz,
CDCl3):
δ 202.4, 136.0, 133.1, 128.7, 128.3, 48.9, 46.3, 44.7, 28.0, 25.4. HRMS (+ESI) m/z calculated for
[M + H]+ 190.1226, found 190.1230.
3-(4-Methylbenzoyl)piperidin-1-ium Chloride (2b). Colorless oil. 1H-NMR (400 MHz, CDCl3):
δ 7.87 (d, J =
8.2 Hz, 2H), 7.32–7.23 (m, 2H), 3.74 (br, 2H), 3.67–3.56 (m, 2H), 3.29 (d, J = 12.2 Hz, 1H), 3.16 (d, J = 12.7 Hz,
1H), 2.94 (dd, J = 12.4, 10.2 Hz, 1H), 2.80–2.64 (m, 1H), 2.41 (s, 3H), 2.10–1.97 (m, 1H), 1.82–1.75 (m, 1H),
1.74–1.62 (m, 1H), 1.48 (t, J = 7.3 Hz, 1H). 13C-NMR (101 MHz, CDCl3):
δ 201.4, 144.1, 133.2, 129.5, 128.5,
48.2, 45.8, 43.7, 27.8, 24.6, 21.6. HRMS (+ESI) m/z calculatedfor [M + H]+ 204.1383, found 204.1387.
1
3-(4-Fluorobenzoyl)piperidin-1-ium Chloride (2c). Yellow oil. H-NMR (400 MHz, CDCl3):
δ 8.00 (dd, J =
8.7, 5.5 Hz, 2H), 7.17–7.13 (m, 2H), 3.63–3.45 (m, 1H), 3.34 (br, 2H), 3.26 (d, J = 12.1 Hz, 1H), 3.12 (d, J =
11.8 Hz, 1H), 2.96–2.82 (m, 1H), 2.72 (t, J = 9.6 Hz, 1H), 2.10–2.05 (m, 1H), 1.86–1.62 (m, 3H). 13C-NMR
(101 MHz, CDCl3):
δ 200.5, 166.8 (d, J = 253.0 Hz), 132.2 (d, J = 3.0 Hz), 131.0 (d, J = 9.0 Hz), 115.9 (d, J =
22.0 Hz), 48.6, 46.1, 44.3, 27.9, 25.0. HRMS (+ESI) m/z calculatedfor [M + H]+ 208.1132, found 208.1136.
1
3-(2-Methylbenzoyl)piperidin-1-ium Chloride (2d). Colorless oil. H-NMR (400 MHz, CDCl3):
δ 7.63 (d, J
= 7.8 Hz, 1H), 7.40–7.36 (m, 1H), 7.32–7.24 (m, 2H), 5.03 (br, 2H), 3.64–3.59 (m, 1H), 3.42 (dd, J = 12.4,
2.8 Hz, 1H), 3.27 (dt, J = 12.4, 3.6 Hz, 1H), 3.05–2.93 (m, 1H), 2.87–2.71 (m, 1H), 2.45 (s, 3H), 2.11–1.99
(m, 1H), 1.84 (tt, J = 7.2, 3.6 Hz, 2H), 1.66–1.51 (m, 1H). 13C-NMR (101 MHz, CDCl3):
δ 204.9, 138.2,
136.8, 132.0, 131.4, 128.1, 125.8, 46.9, 45.4, 45.2, 26.9, 23.7, 21.0. HRMS (+ESI) m/z calculated for [M +
H]+ 204.1383, found 204.1387.
1
3-(2-Naphthoyl)piperidin-1-ium Chloride (2e). Yellow oil. H-NMR (400 MHz, CDCl3):
δ 8.55 (s, 1H),
8.09–7.97 (m, 2H), 7.95–7.85 (m, 2H), 7.64–7.55 (m, 2H), 4.29 (br, 2H), 3.94–3.82 (m, 1H), 3.44 (d, J =
11.7 Hz, 1H), 3.30–3.20 (m, 1H), 3.04 (dd, J = 12.3, 10.4 Hz, 1H), 2.90–2.75 (m, 1H), 2.18–2.09 (m, 1H),
1.95–1.84 (m, 2H), 1.80–1.73 (m, 1H). 13C-NMR (101 MHz, CDCl3):
δ 201.3, 135.7, 132.8, 132.6, 130.1,
129.7, 128.7, 128.7, 127.8, 126.9, 124.0, 48.1, 45.7, 43.5, 27.7, 24.3. HRMS (+ESI) m/z calculated for [M +
H]+ 240.1383, found 240.1387.
1
3-Pentanoylpiperidin-1-ium Chloride (2f). Yellow oil. H-NMR (400 MHz, CDCl3):
δ 3.61–3.55 (m, 1H),
3.46 (t, J = 14.0 Hz, 2H), 3.14 (tt, J = 11.5, 3.4 Hz, 1H), 3.03–2.91 (m, 1H), 2.82 (td, J = 12.6, 3.3 Hz, 1H),
2.54–2.43 (m, 2H), 2.18 (d, J = 13.4 Hz, 1H), 2.07–2.04 (m, 1H), 2.00–1.85 (m, 1H), 1.63–1.40 (m, 4H),
1.36–1.30 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C-NMR (101 MHz, CDCl3):
δ
209.7, 45.3, 44.7, 43.9, 40.7,
25.9, 25.4, 22.3, 21.9, 13.8. HRMS (+ESI) m/z calculated for [M + H]+ 170.1539, found 170.1543.
3-Isobutyrylpiperidin-1-ium Chloride (2g). Yellow oil. 1H-NMR (400 MHz, CDCl3):
3.88 (br, 1H),
3.55–3.40 (m, 2H), 3.40–3.27 (m, 2H), 3.05–2.95 (m, 1H), 2.93–2.73 (m, 2H), 2.15–1.93 (m, 3H), 1.58–1.40
δ
(m, 1H), 1.15–1.08 (m, 6H). 13C-NMR (101 MHz, CDCl3):
δ 213.4, 44.9, 43.9, 43.3, 39.3, 25.8, 19.3, 18.6,
17.8. HRMS (+ESI) m/z calculated for [M + H]+ 156.1383, found 156.1386.
3-(Thiophene-2-carbonyl)piperidin-1-ium Chloride (2h). Yellow oil.1H-NMR (400 MHz, CDCl3):
δ 7.82
(d, J = 3.8 Hz, 1H), 7.68 (d, J = 4.9 Hz, 1H), 7.19–7.14 (m, 1H), 3.55–3.44 (m, 1H), 3.33 (d, J = 12.0 Hz,

Molecules 2019, 24, 401
9 of 15
1H), 3.21–3.08 (m, 3H), 3.02–2.93 (m, 1H), 2.77 (t, J = 11.5 Hz, 1H), 2.10–2.07 (m, 1H), 1.91–1.67 (m, 3H).
13C-NMR (101 MHz, CDCl3):
194.7, 143.5, 134.1, 132.1, 128.3, 48.7, 46.0, 29.7, 28.0, 24.9. HRMS (+ESI)
m/z calculated for [M + H]+ 196.0791, found 196.0794.
δ
1
3-Benzoyl-5-phenethylpiperidin-1-ium Chloride (2i). Yellow oil. H-NMR (400 MHz, CDCl3):
δ 8.03 (d, J =
7.3 Hz, 0.45H), 7.96 (d, J = 7.3 Hz, 0.92H), 7.70–7.40 (m, 4H), 7.28–7.02 (m, 5H), 4.29–4.15 (m, 1H), 4.03
(d, J = 4.2 Hz, 1H), 3.72–3.55 (m, 2H), 3.45–3.41 (m, 1H), 3.21–2.85 (m, 2H), 2.77–2.49 (m, 3H), 2.47–2.17
(m, 1H), 2.13–1.99 (m, 1H), 1.91–1.84 (m, 2H), 1.79–1.47 (m, 2H). 13C-NMR (101 MHz, CDCl3):
δ 201.4,
199.0, 161.8, 159.2, 141.2, 140.7, 134.8, 134.3, 134.2, 133.9, 129.1, 129.0, 128.7, 128.7, 128.6, 128.5, 128.3,
128.2, 126.2, 48.7, 47.8, 45.4, 44.8, 37.2, 35.6, 33.9, 33.4, 33.1, 32.6, 31.1, 29.7, 29.7. HRMS (+ESI) m/z
calculated for [M + H]+ 294.1852, found 294.1855.
1
3-Benzoyl-5-methylpiperidin-1-ium Chloride (2j). Colorless oil. H-NMR (400 MHz, CDCl3):
δ 7.98 (d, J =
7.5 Hz, 1.5H), 7.93 (d, J = 7.5 Hz, 0.3H), 7.61–7.57 (m, 1H), 7.51–7.47 (m, 2H), 3.59–3.52 (m, 1H), 3.29 (t, J =
10.8 Hz, 1H), 3.09 (d, J = 12.8 Hz, 0.72H), 3.01 (d, J = 12.8 Hz, 0.24H), 2.74 (t, J = 11.7 Hz, 1H), 2.37 (dd, J =
12.9, 9.0 Hz, 0.18H), 2.25 (dd, J = 12.9, 9.0 Hz, 0.78H), 2.20–2.12 (m, 0.2H), 2.02 (d, J = 13.3 Hz, 0.91H), 1.77
(td, J = 11.2, 7.0 Hz, 0.94H), 1.69–1.60 (m, 0.31H), 1.39–1.22 (m, 2H), 0.91 (dd, J = 13.4, 6.6 Hz, 3H).13C-NMR
(101 MHz, CDCl3):
δ 201.8, 136.0, 133.2, 128.8, 128.3, 53.6, 53.0, 48.4, 47.4, 45.3, 40.4, 36.5, 34.8, 31.5, 29.3,
19.4, 18.8. HRMS (+ESI) m/z calculated for [M + H]+ 204.1383, found 204.1387.
1
3-Benzoyl-5-phenylpiperidin-1-ium Chloride (2k). Colorless oil. H-NMR (400 MHz, CDCl3):
δ 8.02 (d, J
= 7.4 Hz, 1.68H), 7.95 (d, J = 7.4 Hz, 0.32H), 7.61–7.57 (m, 1H), 7.51–7.47 (m, 2H), 7.37–7.19 (m, 5H),
4.43 (br, 2H), 4.06–3.90 (m, 1H), 3.62–3.46 (m, 1H), 3.44–3.41 (m, 0.78H), 3.35–3.33 (m, 0.28H), 3.25–3.12
(m, 1H), 3.05 (t, J = 12.0 Hz, 1H), 2.96–2.87 (m, 0.4H), 2.84 (t, J = 12.1 Hz, 0.76H), 2.31–2.28 (m, 1H),
2.03–1.85 (m, 1H). 13C-NMR (101 MHz, CDCl3):
δ 200.5, 141.8, 141.8, 135.5, 135.4, 133.5, 133.4, 128.9,
128.8, 128.3, 128.4, 127.2, 127.1, 52.0, 51.6, 47.3, 46.5, 43.8, 41.7, 40.0, 38.6, 34.7, 33.1. HRMS (+ESI) m/z
calculated for [M + H]+ 266.1539, found 266.1545.
1
3-Benzoyl-5-(4-methoxyphenyl)piperidin-1-ium Chloride (2l). Colorless oil. H-NMR (400 MHz, CDCl3):
δ
8.00 (d, J = 7.3 Hz, 1.66H), 7.93 (d, J = 7.3 Hz, 0.38H), 7.61–7.57 (m, 1H), 7.54–7.44 (m, 2H), 7.18 (d,
J = 8.6 Hz, 1.61H), 7.13 (d, J = 8.6 H, 0.39H), 6.88–6.84 (m, 2H), 3.80 (s, 2.3H), 3.79 (s, 0.57H), 3.72 (tt,
J = 11.5, 3.4 Hz, 1H), 3.49 (d, J = 12.3 Hz, 0.24H), 3.38 (d, J = 12.3 Hz, 0.82H), 3.28–3.24 (m, 0.88H),
3.20–3.16 (m, 0.18H), 3.03 (dd, J = 13.6, 3.9 Hz, 0.26H), 2.95–2.87 (m, 1.52H), 2.79–2.65 (m, 2H), 2.62
(br, 2H), 2.35–2.32 (m, 0.31H), 2.26–2.17 (m, 0.81H), 2.01–1.84 (m, 1H). 13C-NMR (101 MHz, CDCl3):
δ
203.9, 201.6, 158.4, 158.2, 136.0, 135.9, 135.8, 135.4, 133.2, 133.1, 128.8, 128.3, 128.1, 128.0, 114.0, 113.9,
55.3, 53.5, 53.1, 48.6, 47.2, 45.6, 42.4, 40.6, 38.5, 36.9, 35.1, 33.7. HRMS (+ESI) m/z calculated for [M +
H]+ 296.1645, found 296.1647.
1
3-Benzoyl-5-(4-fluorophenyl)piperidin-1-ium Chloride (2m). Yellow oil. H-NMR (400 MHz, CDCl3):
δ
8.04–7.97 (m, 1.39H), 7.97–7.90 (m, 0.49H), 7.62–7.57 (m, 1H), 7.52–7.47 (m, 2H), 7.23–7.16 (m, 2H),
7.03–6.96 (m, 2H), 3.76 (tt, J = 11.5, 3.6 Hz, 0.72H), 3.68–3.64 (m, 0.29H), 3.50 (d, J = 13.5 Hz, 0.27H),
3.41 (d, J = 12.4 Hz, 0.7H), 3.29–3.21 (m, 1H), 3.12–2.82 (m, 4H), 2.82–2.65 (m, 1H), 2.33 (d, J = 13.2 Hz,
0.28H), 2.26–2.18 (m, 0.81H), 2.17–2.08 (m, 0.24H), 2.02–1.84 (m, 0.75H). 13C-NMR (101 MHz, CDCl3):
δ
203.6, 201.3, 161.7 (d, J = 243.0 Hz), 161.5 (d, J = 243.0 Hz), 139.3 (d, J = 3.0 Hz), 138.7 (d, J = 4.0 Hz),
135.8 (d, J = 8.0 Hz), 133.3 (d, J = 11.0 Hz), 128.8, 128.6, 128.5, 128.3, 115.4 (d, J = 21.0 Hz), 115.23 (d, J =
21.0 Hz),53.1, 52.8, 48.4, 47.1, 45.2, 42.3, 40.4, 38.5, 34.9, 33.6. HRMS (+ESI) m/z calculated for [M + H]+
284.1445, found 284.1453.
1
3-Benzoyl-5-(naphthalen-1-yl)piperidin-1-ium Chloride (2n). Colorless oil. H-NMR (400 MHz, CDCl3):
δ
8.23 (d, J = 8.5 Hz, 1H), 8.05 (d, J = 7.4 Hz, 1.58H), 7.99 (d, J = 7.4 Hz, 0.65H), 7.89 (d, J = 8.0 Hz,
0.69H), 7.84 (d, J = 8.0 Hz, 0.4H), 7.76 (d, J = 8.0 Hz, 0.62H), 7.73 (d, J = 8.0 Hz, 0.33H) 7.65–7.36 (m, 7H),
3.98–3.60 (m, 3H), 3.81–3.42 (m, 1.45H), 3.15 (dd, J=13.6, 4.0 Hz, 0.46H), 3.08–2.97 (m, 1H), 2.83 (t, J =
11.7 Hz, 1H), 2.57 (d, J = 13.5 Hz, 0.45H), 2.38 (d, J = 13.2 Hz, 0.77H), 2.27–2.16 (m,1H), 2.13– 2.00 (m,
2H). 13C-NMR (101 MHz, CDCl3):
δ 203.6, 201.3, 162.9, 162.7, 160.4, 160.3, 139.3, 138.8, 138.7, 135.8,

Molecules 2019, 24, 401
10 of 15
135.8, 133.3, 133.2, 128.8, 128.6, 128.5, 128.3, 115.5, 115.4, 115.3, 115.2, 53.1, 52.8, 48.4, 47.1, 45.2, 42.3,
40.4, 38.5, 34.9, 33.6. HRMS (+ESI) m/z calculated for [M + H]+ 316.1696, found 316.1701.
1
3-Benzoyl-5-(thiophen-2-yl)piperidin-1-ium Chloride (2o). Yellow oil. H-NMR (400 MHz, CDCl3):
δ 8.01
(d, J = 7.3 Hz, 1.67H), 7.93 (d, J = 7.3 Hz, 0.28H), 7.61–7.57 (m, 1H), 7.51–7.47 (m, 2H), 7.31–7.25 (m,
1H), 7.04 (d, J = 1.7 Hz, 1H), 7.00 (dd, J = 5.0, 0.8 Hz, 1H), 4.03 (br, 2H), 3.91 (tt, J = 11.8, 3.3 Hz, 1H),
3.59–3.53 (m, 0.17H), 3.47 (d, J = 12.2 Hz, 2H), 3.38–3.31 (m, 0.24H), 3.29–3.22 (m, 0.9H), 3.13–3.05 (m,
0.35H), 3.02–2.96 (m, 0.89H), 2.93–2.87 (m, 0.22H), 2.77–2.72 (m, 1H), 2.66 (d, J = 9.3 Hz, 1H), 2.40–2.33
(m, 1H), 2.26–2.15 (m, 0.29H), 1.89–1.80 (m, 1H). 13C-NMR (101 MHz, CDCl3):
δ 203.1, 200.7, 147.0,
146.1, 135.7, 133.4, 133.3, 128.9, 128.8, 128.4, 126.8, 126.8, 123.5, 123.3, 123.3, 53.2, 52.7, 47.9, 44.6, 40.3,
37.8, 36.0, 34.7, 34.2, 29.7. HRMS (+ESI) m/z calculated for [M + H]+ 272.1104, found 272.1110.
3-Benzoyl-5-(thiophen-3-yl)piperidin-1-ium Chloride (2p). Yellow oil. 1H-NMR (400 MHz, CDCl3):
δ
8.02–7.99 (m, 1.64H), 7.95–7.90 (m, 0.33H), 7.62–7.57 (m, 1H), 7.55–7.46 (m, 2H), 7.30–7.28 (m, 1H),
7.06–6.98 (m, 2H), 3.78 (tt, J = 11.6, 3.4 Hz, 0.81H), 3.71–3.62 (m, 0.23H), 3.46–3.36 (m, 2H), 3.28 (br,
2H), 3.22–3.01 (m, 2H), 3.02–2.83 (m, 1H), 2.79–2.60 (m, 1H), 2.41–2.32 (m, 1H), 2.26–2.13 (m, 0.31H),
1.92–1.82 (m, 0.89H). 13C-NMR (101 MHz, CDCl3)
δ203.2, 200.3, 143.4, 142.5, 135.4, 133.6, 133.5, 128.9,
128.9, 128.5, 128.4, 126.7, 126.4, 126.1, 125.9, 120.4, 120.1, 51.1, 50.9, 46.9, 46.4, 43.4, 39.8, 34.7, 34.1, 33.1,
29.7. HRMS (+ESI) m/z calculated for [M + H]+ 272.1104, found 272.1110.
1
5-Benzoyl-2-phenylpiperidin-1-ium Chloride (2q). Yellow oil. H-NMR (400 MHz, CDCl3):
δ 8.09–8.02 (m,
1.33H), 7.99–7.94 (m, 0.64H), 7.73–7.64 (m, 0.73H), 7.64–7.55 (m, 1.42H), 7.55–7.48 (m, 2.52H), 7.47–7.44
(m, 1.47H), 7.39–7.34 (m, 2H), 3.88–3.80 (m, 0.36H), 3.79–3.70 (m, 1.41H), 3.61–3.56 (m, 0.59H), 3.48–3.36
(m, 0.75H), 3.21 (dd, J = 13.9, 4.3 Hz, 0.38H), 3.04 (t, J = 11.5 Hz, 0.75H), 2.65 (br, 2H), 2.18–2.11 (m, 1H),
2.02–1.96 (m, 1H), 1.87–1.82 (m, 1H). 13C-NMR (101 MHz, CDCl3):
δ 203.7, 201.9, 136.0, 133.2, 133.1,
132.1, 132.1, 132.0, 128.8, 128.6, 128.5, 128.4, 128.3, 127.6, 127.4, 126.8, 126.6, 61.7, 60.0, 49.5, 47.5, 44.1,
39.5, 33.4, 29.7, 29.3, 28.6. HRMS (+ESI) m/z calculated for [M + H]+ 266.1539, found 266.1545.
1
5-(4-Methoxybenzoyl)-2-(4-methoxyphenyl)piperidin-1-ium Chloride (2r). Yellow oil. H-NMR (400 MHz,
CDCl3):
δ 7.97 (d, J = 8.2 Hz, 0.28H), 7.87 (d, J = 8.2 Hz, 1.92H), 7.32–7.28 (m, 4H), 7.16 (d, J = 7.9 Hz,
2.24H), 4.50 (br, 2H), 3.96–3.86 (m, 1H), 3.78–3.75 (m, 0.17H), 3.67–3.51 (m, 1.87H), 3.48–3.45 (m, 0.19H),
3.24 (dd, J = 13.4, 3.7 Hz, 0.93H), 3.05 (t, J = 11.7 Hz, 0.14H), 2.44 (s, 3.09H), 2.40 (s, 0.19H), 2.34 (s,
2.84H), 2.30 (s, 0.2H), 2.25–2.07 (m, 2H), 1.92–1.84 (m, 2H). 13C-NMR (101 MHz, CDCl3):
138.8, 137.3, 133.1, 129.5, 129.3, 128.6, 126.6, 59.2, 47.0, 39.0, 28.7, 26.5, 21.7, 21.1.
δ 203.1, 144.2,
5-(4-(Trifluoromethyl)benzoyl)-2-(4-(trifluoromethyl)phenyl)piperidin-1-ium Chloride (2s). Yellow oil.
1H-NMR (400 MHz, CDCl3):
8.03 (d, J = 8.1 Hz, 2H), 7.77 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 8.1 Hz, 2H),
δ
7.48 (d, J = 8.3 Hz, 2H), 3.87–3.71 (m, 1H), 3.60 (dt, J = 13.1, 2.1 Hz, 1H), 3.51–3.47 (m, 1H), 3.20 (dd, J
= 13.2, 3.9 Hz, 1H), 2.41–2.24 (m, 1H), 2.14–1.95 (m, 1H), 1.89 (br, 2H), 1.86–1.79 (m, 2H). 13C-NMR
(101 MHz, CDCl3):
δ 202.6, 148.3, 139.2, 134.1 (q, J = 32.6 Hz), 129.3 (q, J = 32.3 Hz), 125.8 (q, J =
3.7 Hz), 125.4 (q, J = 3.8 Hz), 124.2(q, J = 272.7 Hz ), 123.6 (q, J = 273.7 Hz), 60.3, 48.1, 40.7, 30.1, 26.2.
HRMS (+ESI) m/z calculated for [M + H]+ 402.1287, found 402.1309.
3-(Ethoxycarbonyl)piperidin-1-ium Chloride (2t) [23]. Colorless oil. 1H-NMR (400 MHz, CDCl3):
δ 4.13 (q,J
= 7.1 Hz, 2H), 3.16 (dd, J = 12.4, 3.6 Hz, 1H), 2.93 (dt, J = 12.2, 3.9 Hz, 1H), 2.81 (dd, J = 12.4, 9.3 Hz, 1H),
2.72–2.57 (m, 1H), 2.47–2.40 (m, 1H), 2.06–1.94 (m, 2H), 1.75 (br, 2H), 1.71–1.59 (m, 2H), 1.53–1.38 (m, 1H),
1.25 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 174.3, 60.2, 48.5, 46.3, 42.4, 27.3, 25.40, 14.2.
1
3-(Ethoxycarbonyl)-5-methylpiperidin-1-ium Chloride (2u). Yellow oil. H-NMR (400 MHz, CDCl3):
δ
4.34–4.11 (m, 2H), 3.77–3.65 (m, 1H), 3.60–3.54 (m, 1H), 3.47–3.32 (m, 1H), 3.21–3.10 (m, 1H), 3.04–2.92
(m, 0.67H), 2.84 (t, J = 12.6 Hz, 0.35H), 2.75–2.69 (m, 0.64H), 2.65 (d, J = 9.3 Hz, 0.24H), 2.26–2.14 (m,
0.70H), 2.11–2.06 (m, 1.34H), 1.64–1.53 (m, 0.7H), 1.51–1.47 (m, 0.29H), 1.33–1.25 (m, 3H), 1.08 (d, J =
7.8 Hz, 1.77H), 1.01 (d, J = 7.8 Hz). 13C-NMR (101 MHz, CDCl3):
δ 172.2, 171.3, 61.9, 61.2, 49.6, 49.5,

Molecules 2019, 24, 401
11 of 15
44.3, 44.0, 38.7, 36.2, 34.3, 32.2, 25.5, 18.6, 18.3, 14.1, 14.1. HRMS (+ESI) m/z calculatedfor [M + H]+
172.1332, found 172.1339.
1
3-(Ethoxycarbonyl)-5-phenylpiperidin-1-ium Chloride (2v). Colorless oil. H-NMR (400 MHz, CDCl3):
δ
7.37–7.31 (m, 2H), 7.28–7.21 (m, 3H), 4.34–4.13 (m, 2H), 3.51 (d, J = 13.2 Hz, 0.74H), 3.43 (d, J = 13.2 Hz,
0.31H), 3.25–3.20 (m, 1H), 2.91–2.65 (m, 4H), 2.43 (d, J = 13.5 Hz, 0.86H), 2.33 (d, J = 13.5 Hz, 0.44H),
2.22 (br, 2H), 1.99–1.92 (ddd, J = 13.6, 9.6, 4.4 Hz, 0.86H), 1.86–1.77 (q, J = 12.6 Hz, 0.37H ), 1.34–1.28 (m,
3H). 13C-NMR (101 MHz, CDCl3):
δ 174.5, 143.7, 128.6, 128.5, 127.1, 126.8, 126.5, 60.6, 53.0, 47.0, 34.4,
32.9, 29.7, 14.3, 14.2, 12.0. HRMS (+ESI) m/z calculated for [M + H]+ 234.1489, found 234.1493.
1
3-(Ethoxycarbonyl)-5-(4-methoxyphenyl)piperidin-1-ium Chloride (2w). Colorless oil. H-NMR (400 MHz,
CDCl3):
δ 7.18–7.12 (m, 2H), 6.91–6.84 (m, 2H), 4.36–4.09 (m, 2H), 3.81 (s, 3H), 3.50 (d, J = 13.2 Hz,
0.77H), 3.44 (d, J = 13.2 Hz, 0.32H), 3.21 (t, J = 13.5 Hz, 1H), 2.90–2.75 (m, 2H), 2.73 (br, 2H), 2.71–2.59
(m, 2H), 2.40 (d, J = 13.1 Hz, 0.83H), 2.31 (d, J = 13.1 Hz, 0.36H), 1.95–1.87 (ddd, J = 13.6, 9.6, 4.4 Hz,
0.79H), 1.81–1.72 (q, J = 12.6 Hz, 0.34H), 1.34–1.25 (m, 3H). 13C-NMR (101 MHz, CDCl3):
δ 174.4, 173.3,
158.4, 158.2, 135.7, 134.9, 128.0, 114.0, 113.9, 60.7, 60.6, 55.3, 53.0, 52.4, 47.4, 46.8, 39.6, 39.2, 34.5, 33.1,
29.7, 14.3, 14.2. HRMS (+ESI) m/z calculated for [M + H]+ 264.1594, found 264.1598.
1
3-(Ethoxycarbonyl)-5-(4-fluorophenyl)piperidin-1-ium Chloride (2x). Colorless oil. H-NMR (400 MHz,
CDCl3):
δ 7.22–7.16 (m, 2H), 7.05–6.97 (m, 2H), 4.31–4.11 (m, 2H), 3.49 (d, J = 13.3 Hz, 0.7H), 3.43–3.35
(m, 0.33H), 3.16 (d, J = 11.7 Hz, 1H), 2.89–2.81 (m, 1H), 2.76–2.59 (m, 3H), 2.44–2.35 (m, 0.72H), 2.31–2.26
(m, 0.34H), 2.00 (br, 2H), 1.92–1.85 (ddd, J = 13.6, 9.6, 4.4 Hz, 0.84H), 1.81–1.72 (q, J = 12.6 Hz, 0.40H),
1.34–1.26 (m, 3H). 13C-NMR (101 MHz, CDCl3):
δ 174.1, 172.8, 161.7 (d, J = 244.0 Hz), 161.6 (d, J =
243.0 Hz), 139.0 (d, J = 3.0 Hz), 138.0 (d, J = 3.0 Hz), 128.5 (d, J = 8.0 Hz), 128.4 (d, J = 8.0 Hz), 115.5 (d, J
= 22.0 Hz), 115.4 (d, J = 21.0 Hz), 60.8, 52.7, 51.7, 46.8, 46.6, 41.9, 41.1, 39.4, 39.0, 34.2, 32.9, 29.7, 14.3,
14.2. HRMS (+ESI) m/z calculated for [M + H]+ 252.1394, found 252.1399.
1
3-(Benzyloxy)-5-(ethoxycarbonyl)piperidin-1-ium Chloride (2y). Yellow oil. H-NMR (400 MHz, CDCl3):
δ
7.55–7.30 (m, 5H), 4.91 (br, 2H), 4.70–4.62 (m, 0.62H), 4.64–4.54 (m, 1.62H), 4.24–4.04 (m, 2H), 3.94–3.80 (m,
1H), 3.62–3.33 (m, 2H), 3.21–3.02 (m, 1H), 3.03–2.78 (m, 2H), 2.45–2.41 (m, 0.56H), 2.34–2.31 (m, 0.52H),
1.92–1.79 (m, 0.56H), 1.79–1.66 (m, 0.49H), 1.28–1.23 (m, 3H). 13C-NMR (101 MHz, CDCl3):
δ 172.3, 171.8,
137.6, 128.5, 128.5, 127.9, 127.9, 127.8, 127.6, 71.1, 70.7, 70.6, 68.5, 61.4, 61.2, 47.6, 46.8, 45.4, 44.9, 37.5, 35.6,
31.6, 30.2, 14.1, 14.1. HRMS (+ESI) m/z calculated for [M + H]+ 264.1594, found 264.1598.
1
1,2,3,4-Tetrahydroquinoxaline (4a) [29]. Yellow oil. H-NMR (400 MHz, CDCl3):
δ 6.63–6.61 (m, 2H),
6.56–6.47 (m, 2H), 3.45 (s, 4H). 13C-NMR (101 MHz, CDCl3) δ 133.7, 118.8, 114.7, 41.4.
1
2-Phenyl-1,2,3,4-tetrahydroquinoxaline (4b) [40]. White solid. H-NMR (400 MHz, CDCl3):
δ 7.50–7.39
(m, 4H), 7.38–7.34 (m, 1H), 6.70–6.67 (m, 2H), 6.64 –6.61 (m, 2H), 4.52 (dd, J = 8.2, 3.1 Hz, 1H), 3.92 (br,
2H), 3.50 (dd, J = 11.0, 3.1 Hz, 1H), 3.37 (dd, J = 11.0, 8.2 Hz, 1H). 13C-NMR (101 MHz, CDCl3)
δ 141.9,
134.2, 132.9, 128.7, 127.9, 127.0, 118.9, 118.8, 114.7, 114.5, 54.8, 49.2.
1
2-(4-Chlorophenyl)-4-methyl-3,4-dihydroquinazoline (4c). Yellow solid. H-NMR (400 MHz, CDCl3):
δ 7.79
(d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.27–7.23 (m, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.13–7.09 (m, 1H),
7.04 (d, J = 7.4 Hz, 1H), 4.91 (q, J = 6.5 Hz, 1H), 1.54 (d, J = 6.5 Hz, 3H). 13C-NMR (101 MHz, CDCl3):
δ
152.9, 141.0, 136.7, 133.9, 128.8, 128.1, 128.0, 125.8, 125.1, 125.0, 123.3, 49.3, 25.6.
1
4-(4-Chlorophenyl)-1-methyl-1,2-dihydrophthalazine (4d). Yellow solid. H-NMR (400 MHz, CDCl3):
δ
7.59 (d, J = 8.4 Hz, 2H), 7.48–7.42 (m, 3H), 7.34–7.27 (m, 1H), 7.25–7.22 (m, 2H), 6.07 (br, 1H), 4.41 (q, J =
6.4 Hz, 1H), 1.55 (d, J = 6.5 Hz, 3H). 13C-NMR (101 MHz, CDCl3):
δ 148.1, 137.2, 135.0, 134.1, 130.7,
129.7, 128.6, 127.3, 125.3, 125.0, 123.7, 49.9, 18.1.
1
1,2,3,4-Tetrahydroquinoline (4e) [41]. Colorless oil. H-NMR (400 MHz, CDCl3):
δ 7.08–7.03 (m, 2H),
6.72–6.68 (m, 1H), 6.55 (dd, J = 7.8, 0.6 Hz, 1H), 3.84 (br, 1H), 3.42–3.32 (m, 2H), 2.85 (t, J = 6.4 Hz, 2H),
2.08–1.97 (m, 2H). 13C-NMR (101 MHz, CDCl3)
δ
144.9, 129.6, 126.8, 121.5, 117.0, 114.3, 42.1, 27.1, 22.3.

Molecules 2019, 24, 401
12 of 15
1,2,3,4-Tetrahydroisoquinolin-2-ium Chloride (4f) [41]. Colorless oil. 1H-NMR (400 MHz, CDCl3):
δ
7.27–7.18 (m, 2H), 7.18–7.13 (m, 1H), 7.13–7.07 (m, 1H), 5.47 (br, 2H), 4.27 (s, 2H), 3.38 (t, J = 6.1 Hz,
2H), 3.08 (t, J = 6.1 Hz, 2H). 13C-NMR (101 MHz, CDCl3)
δ
136.1, 134.9, 129.4, 126.3, 126.0, 125.8, 48.4,
44.0, 29.3.
1
1,2,3,4-Tetrahydro-1,5-naphthyridine (4g) [42]. Yellow oil. H-NMR (400 MHz, CDCl3):
δ 7.88 (d, J =
4.5 Hz, 1H), 6.91 (dd, J = 8.0, 4.7 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 3.39–3.24 (m, 2H), 2.96 (t, J = 6.5 Hz,
2H), 2.09–2.02 (m, 2H). 13C-NMR (101 MHz, CDCl3) δ 151.2, 137.9, 124.4, 121.9, 120.2, 41.5, 30.3, 21.8.
1
1,2,3,4-Tetrahydro-1,10-phenanthroline (4h) [43]. Yellow oil. H-NMR (400 MHz, CDCl3):
δ 8.71 (d, J
= 3.1 Hz, 1H), 8.03 (d, J = 8.2 Hz, 1H), 7.32 (dd, J = 8.2, 4.2 Hz, 1H), 7.18 (d, J = 8.2 Hz, 1H), 7.00 (d,
J = 8.2 Hz, 1H), 5.95 (s, 1H), 3.60–3.52 (m, 2H), 2.95 (t, J = 6.3 Hz, 2H), 2.17–2.04 (m, 2H). 13C-NMR
(101 MHz, CDCl3) δ 147.0, 140.7, 137.5, 135.9, 129.1, 127.4, 120.6, 116.6, 113.1, 41.3, 27.1, 21.8.
Ethyl 1,4,5,6-tetrahydropyridine-3-carboxylate (intermediate C) [12]. Yellow oil. 1H-NMR (400 MHz,
CDCl3):
δ 7.48 (d, J = 6.1 Hz, 1H), 4.45 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.27–3.15 (m, 2H), 2.34 (t, J =
6.2 Hz, 2H), 1.82 (dt, J = 11.9, 6.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H).
3.2. The Stereochemical Assignment of Disubstituted Piperidines
2v (41.2 mg, 0.15 mmol) and l-bromopropane (30.1 mg, 0.23 mmol) were refluxed in absolute
ethanol (2 mL) with sodium bicarbonate (47.7 mg, 0.45 mol) for 18 h. The mixture was filtered through
a pad of Celite. The inorganic salts were washed with several portions of fresh ethanol. The combined
filtrates were evaporated in vacuo and the residue was purified by flash column chromatography to
obtain compounds 5 (20.2 mg, 0.07 mmol, 46.5%) and 6 (5.4 mg, 0.02 mmol, 13.3%).
1
trans-Ethyl 1-butyl-5-phenylpiperidine-3-carboxylate (
5
) [39]. Yellow oil. H-NMR (400 MHz, CDCl3)
δ
7.30 (d, J = 4.8 Hz, 4H), 7.23–7.17 (m, 1H), 4.23–4.15 (m, 2H), 3.29 (d, J = 9.6 Hz, 1H), 3.16–3.09 (m, 1H),
2.87 (dd, J = 11.4, 4.0 Hz 1H), 2.78–2.68 (m, 1H), 2.46–2.11 (m, 5H), 1.69–1.62 (m, 1H), 1.57–1.38 (m, 2H),
1.38 (m, 5H), 0.91 (t, J = 7.3 Hz, 3H).
cis-Ethyl 1-butyl-5-phenylpiperidine-3-carboxylate (6 δ
) [39]. Yellow oil. 1H-NMR (400 MHz, CDCl3)
7.40–7.30 (m, 2H), 7.24–7.19 (m, 3H),4.16 (q, J = 7.6 Hz, 1H), 3.26 (dt, J = 11.8 Hz, 1.6 Hz 1H), 3.04
(dt, J = 11.8 Hz, 1.6 Hz 1H), 2.95–2.82 (m, 1H), 2.82–2.68 (m, 1H), 2.42 (t, J = 7.2 Hz, 2H), 2.24 (d, J =
12.6 Hz, 1H), 2.05 (t, J = 11.3 Hz, 1H), 1.97 (t, J = 10.8 Hz, 1H), 1.64 (q, J = 12.3 Hz, 1H), 1.57–1.44 (m,
2H), 1.39–1.31 (m, 2H), 1.26 (t, J = 7.4 Hz, 3H), 0.94 (t, J = 7.3 Hz, 1H).
4. Conclusions
In conclusion, we have developed a HMPA-catalyzed metal-free transfer hydrogenation method
for the reduction of pyridines. The functional group tolerance of this method provides an easy
access method to various piperidines with ester or ketone groups at the C-3 position. The suitability
of the method for the reduction of other N-heteroarenes has also been demonstrated. Efforts to
extend the application of chiral HMPA derivatives in metal free pyridine reduction with HSiCl3 are
currently underway.
Supplementary Materials: The following are available online: General experimental procedures, substrates,
product characterization data, 1H- and 13C-NMR spectra substrates and NMR spectra.
Author Contributions: Y.F. performed the experiments and analyzed the results. J.S. conceived and designed the
experiments and wrote the paper.
Funding: We are grateful for financial support from the National Natural Science Foundation of China (Project
No. 21402185).
Conflicts of Interest: The authors declare no conflict of interest.

Molecules 2019, 24, 401
13 of 15
References
1.
2.
3.
Källström, S.; Leino, R. Synthesis of pharmaceutically active compounds containing a disubstituted
piperidine framework. Bioorg. Med. Chem. 2008, 16, 601–635. [CrossRef]
Cadu, A.; Upadhyay, P.K.; Andersson, P.G. Iridium-Catalyzed Asymmetric Hydrogenation of Substituted
Pyridines. Asian J. Org. Chem. 2013, 2, 1061–1065. [CrossRef]
Chang, M.; Huang, Y.; Liu, S.; Chen, Y.; Krska, S.W.; Davies, I.W.; Zhang, X. Asymmetric Hydrogenation
of Pyridinium Salts with an Iridium Phosphole Catalyst. Angew. Chem. Int. Ed. 2014, 53, 12761–12764.
[CrossRef] [PubMed]
4.
Chen, M.-W.; Ye, Z.-S.; Chen, Z.-P.; Wu, B.; Zhou, Y.-G. Enantioselective synthesis of trifluoromethyl
substituted piperidines with multiple stereogenic centers via hydrogenation of pyridinium hydrochlorides.
Org. Chem. Front. 2015, 2, 586–589. [CrossRef]
5.
6.
7.
Glorius, F. Asymmetric hydrogenation of aromatic compounds. Org. Biomol. Chem. 2005, 3, 4171–4175.
[CrossRef] [PubMed]
Glorius, F.; Spielkamp, N.; Holle, S.; Goddard, R.; Lehmann, C.W. Efficient Asymmetric Hydrogenation of
Pyridines. Angew. Chem. Int. Ed. 2004, 43, 2850–2852. [CrossRef] [PubMed]
Huang, W.-X.; Wu, B.; Gao, X.; Chen, M.-W.; Wang, B.; Zhou, Y.-G. Iridium-Catalyzed Selective
Hydrogenation of 3-Hydroxypyridinium Salts: A Facile Synthesis of Piperidin-3-ones. Org. Lett. 2015, 17,
1640–1643. [CrossRef]
8.
9.
Huang, W.-X.; Yu, C.-B.; Ji, Y.; Liu, L.-J.; Zhou, Y.-G. Iridium-Catalyzed Asymmetric Hydrogenation of
Heteroaromatics Bearing a Hydroxyl Group, 3-Hydroxypyridinium Salts. ACS Catal. 2016, 6, 2368–2371.
[CrossRef]
Iimuro, A.; Higashida, K.; Kita, Y.; Mashima, K. Asymmetric Hydrogenation of 3-Amido-2-arylpyridinium
Salts by Triply Chloride-Bridged Dinuclear Iridium Complexes Bearing Enantiopure Diphosphine Ligands:
Synthesis of Neurokinin-1 Receptor Antagonist Derivatives. Adv. Synth. Catal. 2016, 358, 1929–1933.
[CrossRef]
˙
10. Karakulina, A.; Gopakumar, A.; Akçok, I.; Roulier, B.L.; LaGrange, T.; Katsyuba, S.A.; Das, S.; Dyson, P.J.
A Rhodium Nanoparticle–Lewis Acidic Ionic Liquid Catalyst for the Chemoselective Reduction of
Heteroarenes. Angew. Chem. Int. Ed. 2016, 55, 292–296. [CrossRef]
11. Legault, C.Y.; Charette, A.B. Catalytic Asymmetric Hydrogenation of N-Iminopyridinium Ylides: Expedient
Approach to Enantioenriched Substituted Piperidine Derivatives. J. Am. Chem. Soc. 2005, 127, 8966–8967.
[CrossRef] [PubMed]
12. Lei, A.; Chen, M.; He, M.; Zhang, X. Asymmetric Hydrogenation of Pyridines: Enantioselective Synthesis of
Nipecotic Acid Derivatives. Eur. J. Org. Chem. 2006, 2006, 4343–4347. [CrossRef]
13. Oshima, K.; Ohmura, T.; Suginome, M. Regioselective Synthesis of 1,2-Dihydropyridines by
Rhodium-Catalyzed Hydroboration of Pyridines. J. Am. Chem. Soc. 2012, 134, 3699–3702. [CrossRef]
[PubMed]
14. Renom-Carrasco, M.; Gajewski, P.; Pignataro, L.; delries, J.G.; Piarulli, U.; Gennari, C.; Lefort, L. A Mixed
Ligand Approach for the Asymmetric Hydrogenation of 2-Substituted Pyridinium Salts. Adv. Synth. Catal.
2016, 358, 2589–2593. [CrossRef]
15. Tang, W.; Sun, Y.; Lijin, X.; Wang, T.; Qinghua, F.; Lam, K.-H.; Chan, A.S. Highly efficient and enantioselective
hydrogenation of quinolines and pyridines with Ir-Difluorphos catalyst. Org. Biomol. Chem. 2010, 8,
3464–3471. [CrossRef] [PubMed]
16. Tang, W.-J.; Tan, J.; Xu, L.-J.; Lam, K.-H.; Fan, Q.-H.; Chan ASC. Highly Enantioselective Hydrogenation of
Quinoline and Pyridine Derivatives with Iridium-(P-Phos) Catalyst. Adv. Synth. Catal. 2010, 352, 1055–1062.
[CrossRef]
17. Wu, J.; Tang, W.; Pettman, A.; Xiao, J. Efficient and Chemoselective Reduction of Pyridines to
Tetrahydropyridines and Piperidines via Rhodium-Catalyzed Transfer Hydrogenation. Adv. Synth. Catal.
2012, 355, 35–40. [CrossRef]
18. Ye, Z.-S.; Chen, M.-W.; Chen, Q.-A.; Shi, L.; Duan, Y.; Zhou, Y.-G. Iridium-Catalyzed Asymmetric
Hydrogenation of Pyridinium Salts. Angew. Chem. Int. Ed. 2012, 51, 10181–10184. [CrossRef]
19. Zheng, C.; You, S.-L. Transfer hydrogenation with Hantzsch esters and related organic hydride donors.
Chem. Soc. Rev. 2012, 41, 2498–2518. [CrossRef]

Molecules 2019, 24, 401
14 of 15
20. Rossi, S.; Benaglia, M.; Massolo, E.; Raimondi, L. Organocatalytic strategies for enantioselective metal-free
reductions. Catal. Sci. Technol 2014, 4, 2708–2723. [CrossRef]
21. Zhou, Y.-G. Asymmetric Hydrogenation of Heteroaromatic Compounds. Acc. Chem. Res. 2007, 40, 1357–1366.
[CrossRef] [PubMed]
22. Wang, D.-S.; Chen, Q.-A.; Lu, S.-M.; Zhou, Y.-G. Asymmetric Hydrogenation of Heteroarenes and Arenes.
Chem. Rev. 2012, 112, 2557–2590. [CrossRef] [PubMed]
23. Irfan, M.; Petricci, E.; Glasnov, T.N.; Taddei, M.; Kappe, C.O. Continuous Flow Hydrogenation of
Functionalized Pyridines. Eur. J. Org. Chem. 2009, 2009, 1327–1334. [CrossRef]
24. Miyamura, H.; Suzuki, A.; Yasukawa, T.; Kobayashi, S. Polysilane-Immobilized Rh–Pt Bimetallic
Nanoparticles as Powerful Arene Hydrogenation Catalysts: Synthesis, Reactions under Batch and Flow
Conditions and Reaction Mechanism. J. Am. Chem. Soc. 2018, 140, 11325–11334. [CrossRef] [PubMed]
25. Mahdi, T.; del Castillo, J.N.; Stephan, D.W. Metal-Free Hydrogenation of N-Based Heterocycles.
Organometallics 2013, 32, 1971–1978. [CrossRef]
26. Liu, Y.; Du, H. Metal-Free Borane-Catalyzed Highly Stereoselective Hydrogenation of Pyridines. J. Am.
Chem. Soc. 2013, 135, 12968–12971. [CrossRef]
27. Zhou, Q.; Zhang, L.; Meng, W.; Feng, X.; Yang, J.; Du, H. Borane-Catalyzed Transfer Hydrogenations of
Pyridines with Ammonia Borane. Org. Lett. 2016, 18, 5189–5191. [CrossRef]
28. Gandhamsetty, N.; Park, S.; Chang, S. Selective Silylative Reduction of Pyridines Leading to Structurally
Diverse Azacyclic Compounds with the Formation of sp3 C–Si Bonds. J. Am. Chem. Soc. 2015, 137,
15176–15184. [CrossRef]
29. Liu, Z.-Y.; Wen, Z.-H.; Wang, X.-C. B(C6F5)3-Catalyzed Cascade Reduction of Pyridines. Angew. Chem. Int. Ed.
2017, 56, 5817–5820. [CrossRef]
30. Rueping, M.; Antonchick, A.P. Organocatalytic Enantioselective Reduction of Pyridines. Angew. Chem.
Int. Ed. 2007, 46, 4562–4565. [CrossRef]
31. Malkov, A.V.; Vranková, K.; Stoncˇius, S.; Kocˇovský, P. Asymmetric Reduction of Imines with Trichlorosilane,
Catalyzed by Sigamide, an Amino Acid-Derived Formamide: Scope and Limitations. J. Org. Chem. 2009, 74,
5839–5849. [CrossRef] [PubMed]
32. Guizzetti, S.; Benaglia, M. Trichlorosilane-Mediated Stereoselective Reduction of C=N Bonds. Eur. J.
Org. Chem. 2010, 2010, 5529–5541. [CrossRef]
33. Jones, S.; Zhao, P. Evaluating dynamic kinetic resolution strategies in the asymmetric hydrosilylation of
cyclic ketimines. Tetrahedron Asymmetry 2014, 25, 238–244. [CrossRef]
34. Orlandi, M.; Tosi, F.; Bonsignore, M.; Benaglia, M. Metal-Free Reduction of Aromatic and Aliphatic Nitro
Compounds to Amines: A HSiCl3-Mediated Reaction of Wide General Applicability. Org. Lett. 2015, 17,
3941–3943. [CrossRef] [PubMed]
35. Hu, X.-Y.; Zhang, M.-M.; Shu, C.; Zhang, Y.-H.; Liao, L.-H.; Yuan, W.-C.; Zhang, X.-M.
Enantioselective Lewis-Base-Catalyzed Asymmetric Hydrosilylation of Substituted Benzophenone N-Aryl
Imines: Efficient Synthesis of Chiral (Diarylmethyl)amines. Adv. Synth. Catal. 2014, 356, 3539–3544.
[CrossRef]
36. Barrulas, P.C.; Genoni, A.; Benaglia, M.; Burke, A.J. Cinchona-Derived Picolinamides: Effective
Organocatalysts for Stereoselective Imine Hydrosilylation. Eur. J. Org. Chem. 2014, 2014, 7339–7342.
[CrossRef]
37. Warner, C.J.A.; Reeder, A.T.; Jones, S. P-Chiral phosphine oxide catalysed reduction of prochiral ketimines
using trichlorosilane. Tetrahedron Asymmetry 2016, 27, 136–141. [CrossRef]
38. Ye, J.; Wang, C.; Chen, L.; Wu, X.; Zhou, L.; Sun, J. Chiral Lewis Base-Catalyzed, Enantioselective Reduction
of Unprotected β-Enamino Esters with Trichlorosilane. Adv. Synth. Catal. 2016, 358, 1042–1047. [CrossRef]
39. Kippo, T.; Hamaoka, K.; Ueda, M.; Fukuyama, T.; Ryu, I. Bromoallylation of Alkenes Leading to 4-Alkenyl
Bromides Based on Trapping of β-Bromoalkyl Radicals. Org. Lett. 2017, 19, 5198–5200. [CrossRef]
40. Zhang, Y.; Zhu, J.; Xia, Y.-T.; Sun, X.-T.; Wu, L. Efficient Hydrogenation of Nitrogen Heterocycles Catalyzed
by Carbon-Metal Covalent Bonds-Stabilized Palladium Nanoparticles: Synergistic Effects of Particle Size
and Water. Adv. Synth. Catal. 2016, 358, 3039–3045. [CrossRef]
41. Laval, S.; Dayoub, W.; Pehlivan, L.; Métay, E.; Favre-Reguillon, A.; Delbrayelle, D.; Mignani, G.; Lemaire, M.
Straightforward access to cyclic amines by dinitriles reduction. Tetrahedron 2014, 70, 975–983. [CrossRef]

Molecules 2019, 24, 401
15 of 15
42. Xuan, Q.; Song, Q. Diboron-Assisted Palladium-Catalyzed Transfer Hydrogenation of N-Heteroaromatics
with Water as Hydrogen Donor and Solvent. Org. Lett. 2016, 18, 4250–4253. [CrossRef] [PubMed]
43. Eisenberger, P.; Bestvater, B.P.; Keske, E.C.; Crudden, C.M. Hydrogenations at Room Temperature and
Atmospheric Pressure with Mesoionic Carbene-Stabilized Borenium Catalysts. Angew. Chem. Int. Ed. 2015
,
54, 1433–7851. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds 1a, 1o and 1p are available from the authors.
©
2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).